Global tuberculosis report 2017

WHO has published a global TB report every year since 1997. The main aim of the report is to provide a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease at global, regional and country levels. This is done in the context of recommended global TB strategies and targets endorsed by WHO’s Member States and broader development goals set by the United Nations. The data in this report are updated annually.

To read the full report on the WHO website go to: http://www.who.int/tb/publications/global_report/en/

Transforming Intergrated Care in the Community (TICC)

Transforming Integrated Care in the Community (TICC) has secured more than €4.8 million of European funding in this €8 million cross-border partnership involving 14 organisations from the UK, France, the Netherlands and Belgium. The project was approved and funded by the EU Interreg 2 Seas Programme 2014-2020 (co-funded by the European Regional Development Fund) which has supported the project over four years.

TICC will create systemic change in health & social care, providing services better suited to our ageing population by addressing holistic needs. It will present a methodology to overcome blocking points in transferring socially innovative service models from one area to another. This will be tested via the implementation of the Buurtzorg integrated care at home model which consists of self-managing teams of 12 staff working at neighbourhood level handling every aspect of care & business. This model significantly reduces the back office, simplifies IT & coaches rather than manages, providing better outcomes for people, lower costs, fewer unplanned hospital admissions & consistency of care. TICC will enable other health/social care organisations to implement new ideas; increase staff productivity, recruitment and retention as well as improving patient satisfaction & decreasing costs, emergency admissions and staff absences. It aims to postpone the moment when residential or end of life care is needed.

To read more about TICC go to: Transforming Intergrated Care in the Community (TICC) – Buurtzorg International

Database of experts in the field of health

Application for inclusion in the database to support the Expert Panel on effective ways of investing in health

The European Commission has published the above-mentioned call addressed to experts who wish to be included in the database from which individuals are chosen to support the work of the Expert Panel on Health. These experts will be included in a database according to their field of expertise and knowledge.  They will be called only if/when the members of the Expert Panel would request specific expertise and support, and therefore inclusion in the database offers no guarantees of being contacted by the Commission.

To read more and to download the application form on the European Commission website go to: Database of Experts – European Commission

ECHOES: European Community Health Worker Internet Survey

Take part in the largest ever survey of Community Health Workers, taking place all over Europe.

You can take part if you…

• Are aged 18 or over AND;
• Work with gay, bisexual and other Men who have Sex with Men (MSM) now or in the last 12 months AND;
• Deliver sexual health support for gay, bisexual and other MSM in community settings (not in a hospital or clinic).

To read more and to take part in the survey go to: ECHOES: European Community Health Worker Internet Survey

State of children’s medicines in the EU

The European Commission had presented a report to the European Parliament and the Council, on progress made in children’s medicines since the Paediatric Regulation came into force 10 years ago. It concludes that positive advances in the development of medicines for children could not have been achieved without specific EU legislation – e.g. the authorisation of 260 new medicines. The Paediatric Regulation also gives a good return on investment. However, the report acknowledges that more effort is needed to combine the effects of the Paediatric with those of the Orphan medicines Regulation to address shortcomings in treating rare diseases in children.

Commenting on the report, VytenisAndriukaitis, Commissioner for Health and Food Safety, said: “Whereas I am pleased with the overall progress made in improving children’s access to safe, tailored medicines, I am committed to extending these positive gains to children with rare diseases. When we consider the advances in adult oncology, it upsets me deeply that we have not made the same progress in treating the cancers that affect children. In the next 10 years we must focus on making similar breakthroughs for children, by combining the incentives under the Orphans and the Paediatric Regulations, and by ensuring that the European Reference Networks – in particular ‘ERN PaedCan’ on paediatric cancer, reach full capacity”.

To read more about this on the European Commission website go to: http://europa.eu/rapid/press-release_IP-17-4121_en.htm

Scientific Advice on breast implants and health

The European Commission and its Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) have published two Scientific Advices related to breast implants and health, requested by the European Commission. These are on:

1) new scientific information on the safety of PIP breast implants

The first piece of advice concerns whether there is sufficient new scientific information on the safety of PIP breast implants to warrant an update of the 2014 SCENIHR Opinion. Based on the scientific information it has gathered and evaluated, the SCHEER concludes that this is not the case at present

2) the possible association between breast implants and anaplastic large cell lymphoma (ALCL).

The second piece of advice is on the state of scientific knowledge on a possible association between breast implants and anaplastic large cell lymphoma. The SCHEER concluded that, at present, there is insufficient scientific information available to establish a methodologically robust risk assessment on the potential association of breast implants with the development of ALCL.

To read the full report and advice on the European Commission website go to: http://ec.europa.eu/newsroom/sante/newsletter-specific-archive-issue.cfm?newsletter_service_id=327&newsletter_issue_id=3209

Polio in the EU

This year on World Polio Day the WHO European Region is celebrating the 15th anniversary of being certified free from poliomyelitis (polio). Achieving this back in 2002 was a vital step forward for both the Region and the world on the path towards global eradication of this crippling disease. While this target is now closer than ever before, the threat from polioviruses still hangs over the Region, and maintaining and improving vaccination coverage is as important as ever.

According to Professor David Salisbury, Chair of the Global Certification Commission and European Regional Certification Commission for Poliomyelitis Eradication, “The threat from polioviruses and the possibility of outbreaks remains very real. The Region must not ease up on either its actions or its political commitment to preserving its polio-free status.”

 

To read more about this on the WHO Europe website go to: http://www.euro.who.int/en/health-topics/communicable-diseases/poliomyelitis/news/news/2017/10/15th-anniversary-of-polio-free-certification-in-the-european-region-but-the-hard-work-to-prevent-future-cases-is-not-over

Advanced therapy medicinal products

Advanced therapy medicinal products are new medical products based on genes (gene therapy), cells (cell therapy) and tissues (tissue engineering). These advanced therapies herald revolutionary treatments of a number of diseases or injuries, such as skin in burns victims, Alzheimer’s, cancer or muscular dystrophy. They have huge potential for patients and industry.

The lack of an EU-wide regulatory framework in the past led to divergent national approaches which hindered patients’ access to products, hampered the growth of this emerging industry and ultimately affected EU competitiveness in a key biotechnology area.

The EU institutions agreed on a Regulation on advanced therapies (Regulation (EC) 1394/2007) designed to ensure the free movement of advanced therapy products within Europe, to facilitate access to the EU market and to foster the competitiveness of European companies in the field, while guaranteeing the highest level of health protection for patients.

To read more about advanced therapy medicinal products on the European Commission website go to: Advanced therapies – European Commission

Mid-term evaluation of the European Commission 3rd Health Programme 2014-2020 – European Commission

The mid-term evaluation of the first three years of the implementation of the third Health Programme 2014-2020 reveals that the European Commission has made major progress towards reaching the programme’s objectives.

Most notably, the Commission has helped to:

  • establish 24 European Reference Networks for rare disease patients who can now benefit from the best expertise available in Europe,
  • increase Member States’ capacity-building potential to respond to outbreaks such as Ebola and Zika viruses,
  • and strengthen the EU’s migration policy by helping EU countries cope with the health needs of migrants and refugees and training health professionals and support staff.

Other achievements of the health programme include sharing of good practices in areas as diverse as alcohol reduction, cancer screening, HIV/AIDS and TB prevention, additional support for EU health legislation on medicinal products and medical devices, the eHealth Network activities and Health Technology Assessment.

To read the mid-term evaluation in full go to: https://ec.europa.eu/health/sites/health/files/programme/docs/2014-2020_evaluation_midtermreport_en.pdf

EHMA 2018 Annual Conference

The EHMA 2018 Annual Conference will take place in Budapest, Hungary, at Semmelweis University from 20 – 22 June 2018. The theme, “Making it happen” aims to raise discussions about delivering change and overcoming challenges in policy implementation.

As EHMA Member, (through the Health and Europe Centre – contact us if you are interested in attending) you will have access to extra treatment upon arrival and a complimentary Gala dinner pass, a 100 EUR extra discount on the fees, the opportunity of becoming an EHMA Ambassador and attending the conference for free, and 10% for the group of more than 5 attendees from the same organisation.

Pin it in your agenda and do not miss the Super Early Bird fee available on the Conference website as from Tuesday 26th. You can discover more about the EHMA 2018 Annual Conference and follow the news on the upcoming Call for Abstracts on www.ehma2018.org.